Article
Radiology, Nuclear Medicine & Medical Imaging
Jong Keon Jang, Jae Ho Byun, Ji Hun Kang, Jung Hee Son, Jin Hee Kim, Seung Soo Lee, Hyoung Jung Kim, Changhoon Yoo, Kyu-pyo Kim, Seung-Mo Hong, Dong-Wan Seo, Song Cheol Kim, Moon-Gyu Lee
Summary: The study evaluated the ability of CT-determined resectability to predict R0 resection in patients with PDAC after neoadjuvant FOLFIRINOX chemotherapy, finding a relatively low sensitivity and specificity. Low-contrast enhancement of soft tissue contacting artery may enhance the ability of CT to predict R0 resection.
EUROPEAN RADIOLOGY
(2021)
Review
Oncology
Hao-Qi Zhang, Jing Li, Chun-Lu Tan, Yong-Hua Chen, Zhen-Jiang Zheng, Xu-Bao Liu
Summary: This review compiles data from five randomized controlled trials (RCTs) regarding risk factors affecting the prognosis of patients with R-PA and discusses potential reasons for the varying outcomes.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Review
Oncology
Susanna W. L. de Geus, Teviah E. Sachs
Summary: Over the past decade, neoadjuvant therapy has become the standard of care for borderline resectable and locally advanced pancreatic cancer. However, there is still debate regarding its value for clearly resectable disease. Meta-analyses suggest that neoadjuvant therapy can be offered as an acceptable standard of care, with recent studies showing superior survival for patients who tolerate neoadjuvant FOLFIRINOX. Ongoing randomized controlled trials are expected to provide more conclusive recommendations.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Takehiro Okabayashi, Kenta Sui, Motoyasu Tabuchi, Takahiro Murokawa, Shinichi Sakamoto, Jun Iwata, Sojiro Morita, Nobuto Okamoto, Tatsuo Iiyama, Yasuhiro Shimada, Toshiyoshi Fujiwara
Summary: This study evaluated the efficacy of neoadjuvant therapy for resectable pancreatic cancer and found that it can reduce the recurrence rate and improve the consistency of clinical and pathological staging.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Roberto Alva-Ruiz, Lavanya Yohanathan, Jennifer A. Yonkus, Amro M. Abdelrahman, Lindsey A. Gregory, Thorvadur R. Halfdanarson, Amit Mahipal, Robert R. McWilliams, Wen Wee Ma, Christopher L. Hallemeier, Rondell P. Graham, Travis E. Grotz, Rory L. Smoot, Sean P. Cleary, David M. Nagorney, Michael L. Kendrick, Mark J. Truty
Summary: This study reviewed patients with borderline resectable/locally advanced pancreatic ductal adenocarcinoma who underwent neoadjuvant chemotherapy followed by either continued first-line chemotherapy or chemotherapy switch. The results showed that patients undergoing chemotherapy switch with subsequent curative-intent surgical resection did not have significantly different recurrence-free survival and overall survival compared to those receiving first-line chemotherapy. However, patients undergoing chemotherapy switch without subsequent resection had significantly worse overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Kazuhisa Takeda, Yu Sawada, Yasuhiro Yabushita, Yuki Honma, Takafumi Kumamoto, Jun Watanabe, Ryusei Matsuyama, Chikara Kunisaki, Toshihiro Misumi, Itaru Endo
Summary: The study found that neoadjuvant chemotherapy (NAC) may improve the prognosis of high-risk patients with resectable colorectal liver metastases (CRLMs) who have two or more risk factors. In these high-risk patients, the 5-year overall survival rate was significantly higher in the NAC group compared to the upfront hepatectomy group.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Oncology
Jacob L. van Dam, Quisette P. Janssen, Marc G. Besselink, Marjolein Y. Homs, Hjalmar C. van Santvoort, Geertjan van Tienhoven, Roeland F. de Wilde, Johanna W. Wilmink, Casper H. J. van Eijck, Bas Groot Koerkamp
Summary: This study found that neoadjuvant therapy can improve overall survival in patients with borderline resectable pancreatic cancer. However, more evidence is needed to determine whether it also improves survival in patients with resectable pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Akhil Chawla
Summary: Neoadjuvant therapy is widely accepted in the treatment of borderline resectable and locally advanced pancreatic cancers, but its benefits in patients with resectable disease remain debated. Recent key trials evaluating neoadjuvant chemotherapy for resectable pancreatic cancer have reported their results.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Aurelien Lambert, Lilian Schwarz, Michel Ducreux, Thierry Conroy
Summary: Only 10-20% of patients with resectable pancreatic adenocarcinoma have potentially resectable disease. After surgical extirpation of tumors, up to 80% of patients will develop cancer recurrence, and adjuvant chemotherapy is the best strategy to improve overall survival. Neoadjuvant treatment shows some promising results but still requires further investigation to be validated.
Article
Oncology
Hyun Jeong Jeon, Hye Jeong Jeong, Soo Yeun Lim, So Jeong Yoon, Hongbeom Kim, In Woong Han, Jin Seok Heo, Sang Hyun Shin
Summary: This study aimed to investigate the clinical course of patients with advanced pancreatic cancer who underwent resection following FOLIFIRNOX treatment. The results showed that patients with complete pathologic response (cPR) and nearly complete pathologic response (ncPR) had longer overall survival and disease-free survival. Additionally, adjuvant chemotherapy following neoadjuvant treatment might be beneficial for patient outcomes.
Article
Multidisciplinary Sciences
Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton, Michael T. Tezlaff, Merrick Ross, Carlos Torres-Cabala, Isabella C. Glitza, Fei Duan, Denai R. Milton, Klaus Busam, Lauren Simpson, Jennifer L. McQuade, Michael K. Wong, Jeffrey E. Gershenwald, Jeffrey E. Lee, Ryan P. Goepfert, Emily Z. Keung, Sarah B. Fisher, Allison Betof-Warner, Alexander N. Shoushtari, Margaret Callahan, Daniel Coit, Edmund K. Bartlett, Danielle Bello, Parisa Momtaz, Courtney Nicholas, Aidi Gu, Xuejun Zhang, Brinda Rao Korivi, Madhavi Patnana, Sapna P. Patel, Adi Diab, Anthony Lucci, Victor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte Ariyan, Hussein A. Tawbi
Summary: The combination of Relatlimab and nivolumab improves progression-free survival and has a high pathologic complete response rate in patients with advanced melanoma. This new immunotherapy regimen shows favorable safety compared to other combination immunotherapy regimens.
Article
Multidisciplinary Sciences
Shangtong Liu, Hui Li, Yuhui Xue, Liang Yang
Summary: This study suggests that preoperative neoadjuvant therapy has prognostic value in patients with resectable and borderline resectable pancreatic cancer, as it increases the R0 resection rate and improves overall survival.
Article
Gastroenterology & Hepatology
Young Hoon Choi, Sang Hyub Lee, Min Su You, Bang Sup Shin, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim, Wooil Kwon, Jin-Young Jang, Sun-Whe Kim
Summary: Neoadjuvant FOLFIRINOX is effective in treating BR or LA pancreatic cancer, enabling curative surgery and improving overall survival. Prognosis in these patients can be estimated using serum CA19-9 levels, operative status, and initial FDG-PET SUVmax.
Article
Oncology
Eva Versteijne, Jacob L. van Dam, Mustafa Suker, Quisette P. Janssen, Karin Groothuis, Janine M. Akkermans-Vogelaar, Marc G. Besselink, Bert A. Bonsing, Jeroen Buijsen, Olivier R. Busch, Geert-Jan M. Creemers, Ronald M. van Dam, Ferry A. L. M. Eskens, Sebastiaan Festen, Jan Willem B. de Groot, Bas Groot Koerkamp, Ignace H. de Hingh, Marjolein Y. Homs, Jeanin E. van Hooft, Emile D. Kerver, Saskia A. C. Luelmo, Karen J. Neelis, Joost Nuyttens, Gabriel M. R. M. Paardekooper, Gijs A. Patijn, Maurice J. C. van der Sangen, Judith de Vos-Geelen, Johanna W. Wilmink, Aeilko H. Zwinderman, Cornelis J. Punt, Geertjan van Tienhoven, Casper H. J. van Eijck
Summary: This study investigates the impact of neoadjuvant chemoradiotherapy on the survival of patients with resectable and borderline resectable pancreatic cancer. The results demonstrate that neoadjuvant chemoradiotherapy improves overall survival compared to upfront surgery in these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Eva Versteijne, Ignace H. J. T. de Hingh, Marjolein Y. V. Homs, Martijn P. W. Intven, Joost M. Klaase, Hjalmar C. van Santvoort, Judith de Vos-Geelen, Johanna W. Wilmink, Geertjan van Tienhoven
Summary: There is a global shift towards a neoadjuvant approach for patients with resectable or borderline resectable pancreatic cancer. Randomized studies show that neoadjuvant chemotherapy or chemoradiotherapy improves overall survival. However, more effective chemotherapy regimens, such as FOLFIRINOX and Gemcitabine/Nab-paclitaxel, should be investigated in combination with radiotherapy to further improve outcomes.
FRONTIERS IN ONCOLOGY
(2022)
